Search the Community

Soluble TNF-R1, VEGF and other cytokines as markers of disease activity in systemic lupus erythematosus (SLE) and lupus nephritis (LN). These results indicate that for active LN, sTNF-R1 could be a useful serum cytokine marker, with potential for vascular endothelial growth factor in the urine. PubMed, Lupus, 2019 May 2:961203319845487. (Also see Diagnosis of Lupus and Interleukins) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

High levels of circulating interferons (IFNs) type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Our findings suggest that IFNs contribute to the heterogeneity of clinical manifestations in SLE, and measuring circulating IFNs could assist in designing clinical trials with therapies targeting IFN pathways. PubMed, Arthritis Res Ther, 2019 Apr 29;21(1):107. (Also see Diagnosis of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

T cell receptor β repertoires (TCR) as novel diagnostic markers for systemic lupus erythematosus and rheumatoid arthritis. These characteristics of the TCR repertoire can potentially serve as biomarkers and provide novel insights for disease status and therapeutical targets in autoimmune diseases. PubMed, Ann rheumatologist Dis, 05/17/2019. (Also see Diagnosis of Lupus and Diagnosis of Rheumatoid Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Deltex1 (DTX1) suppresses T cell function and is a biomarker for diagnosis and disease activity of systemic lupus erythematosus (SLE). DTX1 expression in the peripheral blood mononuclear cells was significantly lower in SLE patients and had an inverse correlation with disease activity, indicating that the DTX1 level may be a good disease marker of SLE. PubMed, Rheumatology (Oxford), 01/09/2019. (Also see Diagnosis of Lupus and B Cells and T Cells) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Serum miRNA-371b-5p and miRNA-5100 (MicroRNAs) act as biomarkers for systemic lupus erythematosus (SLE). These results suggested that miR-371b-5p and miR-5100 may act as serum biomarkers for SLE. ScienceDirect, Clinical Immunology, 10/07/2018. (Also see Diagnosis of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). Galectin-9 is a novel, easy to measure hence clinically applicable biomarker to detect the IFN signature in patients with systemic autoimmune diseases such as SLE and APS. PubMed, Ann rheumatologist Dis, 09/05/2018. (Also see Diagnosis of Lupus and Antiphospholipid Syndrome) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Many UK Lupus Patients Face Three–year Diagnosis Delay, Study Reports. It took more than three years for 1,000 Britons with lupus, scleroderma and vasculitis to obtain a correct diagnosis after their symptoms began, a study shows. Lupus News, 03/09/2018. (Also see Diagnosis of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Serum Interleukin-34 Levels Are Elevated in Patients with Systemic Lupus Erythematosus (SLE). Serum IL-34 could be a candidate biomarker for SLE as there are elevated serum levels in treatment–naive SLE patients and a significant decrease after effective treatment was seen. PubMed, Molecules, 2016 Dec 28;22(1). (Also see Diagnosis of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Omics studies: their use in diagnosis and reclassification of systemic lupus erythematosus (SLE) and other systemic autoimmune diseases (SADs). This review summarizes the omics findings for SLE and propose ways of using the data for the identification of new biomarkers, finding new drugs and reclassifying patients not only with SLE, but also with other SADs. Rheumatology, 10/19/2016. (Also see Diagnosis of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

The diagnosis and management of the haematologic manifestations of lupus (SLE). In this review the most common and characteristic haematological manifestations of SLE patients are considered, focusing on their pathogenesis and management. PubMed, J Autoimmun, 2016 Nov;74:139-160. (Also see Diagnosis of Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.